Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control

• المؤلفون الرئيسيون: Shen, Yao An, Shyu, Ing Luen, Lu, Maggie, He, Chun Lin, Hsu, Yen Mei, Liang, Hsiang Fa, Liu, Chih Peng, Liu, Ren Shyan, Shen, Biing Jiun, Wei, Yau Huei, Chuang, Chi Mu
• مؤلفون آخرون: School of Humanities and Social Sciences
• التنسيق: مقال
• اللغة: English
• منشور في: 2015
• الموضوعات: DRNTU::Science::Medicine
• الوصول للمادة أونلاين: https://hdl.handle.net/10356/107443; http://hdl.handle.net/10220/25625
• المؤسسة: Nanyang Technological University

The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil®, the first nanomedicine approved by the US Food and Drug Administrati...